Coal India advances Technology-led Diversification Across Energy & Minerals (See 'Corp Brief') Digital India RISC-V Grand Challenge under C2S Programme awarded to 3 teams (See 'Corp Brief') IBC - Arrangement of funds to enable corporate debtor to clear its liabilities, coupled with transfer of funds from cooperative bank loan account of applicant directly to bank, is not valid loan disbursement under IBC: NCLT (See 'Legal Desk') Vaishnaw highlights ISM 2.0, indigenous design, manufacturing, talent and India's emergence (See 'Corp Brief') SEBI - SEBI, acting as statutory market regulator, is duty-bound to issue a reasoned, speaking order when a decision carries serious civil consequences for acquirer, target company & investors: SAT (See 'Legal Desk') An unsuccessful 'success fee' litigation (See CORP EINSICHT) Centre commemorates World Patient Safety Day 2026 at NIHFW (See 'Corp Brief') BIMSTEC Energy Centre organises 5-Day Capacity Building Programme (See 'Corp Brief') Scindia inaugurates Renovated Guna Head Post Office in MP (See 'Corp Brief') SEBI - Where material on record discloses need for deeper scrutiny, re-appreciation, review or reconsideration of evidence, leave ought to be granted & the appeal should thereafter be decided on merits: HC (See 'Legal Desk') CCI nod for acquisition of equity of Great White Global by ISAF III Onshore Fund (See 'Corp Brief') From Ink and Ledger to Cloud and Cipher: The Bankers' Books Evidence Act, 2026 - A Critical Appraisal of India's Digital Evidentiary Revolution (See CORP EINSICHT) A&C Act - Question whether particular claim is covered by, or falls outside excepted matters clause of works contract is matter squarely within competence of Arbitral Tribunal u/s 16 of Arbitration and Conciliation Act: SC (See 'Legal Desk') CCI approves acquisition of addl share in Azure Power Global by OMERS Infra (See 'Corp Brief') Beneficiaries express confidence in government policies for e-mobility (See 'Corp Brief') Competition Act - Regulatory decisions taken in exercise of statutory powers not subject to review by CCI; authority concerned is not amenable to scrutiny u/s 4 of Competition Act: CCI (See 'Legal Desk') Semicon 2.0 mission to focus semiconductor design & fabrication; to create 1 lakh jobs (See 'Corp Brief') NLMC to host investor meets ahead of RINL land e-auction (See 'Corp Brief') SEBI - Penalty order under SEBI (PFUTP) Regulations unsustainable where foundational findings regarding volume of manually deleted orders & manipulative intent are perverse & contrary to the record: SAT (See 'Legal Desk') Govt reviews Use of Steel from Ship Recycling to Boost Steel Manufacturing (See 'Corp Brief') Inaugural PDUNASS–GNLU Executive Program on Labour Law concludes at Gandhinagar (See 'Corp Brief') Capital Market - Release of escrow amount maintained for buyback does not bar separate inquiry into alleged fraud under PFUTP Regulations: SC (See 'Legal Desk')

Print

MoS reaffirms India's commitment to global pharmaceutical standardization

Published: Feb 06, 2025

By TIOLCorplaws News Service

NEW DELHI, FEB 06, 2025: UNION Minister of State for Health and Family Welfare, Anupriya Patel delivered the keynote address at the 15th International Meeting of World Pharmacopoeias (IMWP), hosted by the Indian Pharmacopoeia Commission (IPC) under the aegis of the Ministry of Health and Family Welfare, Government of India, in collaboration with the World Health Organization (WHO), here today. The meeting brought together global pharmacopoeial leaders, regulatory authorities, and industry stakeholders to deliberate on key issues related to pharmaceutical standards and harmonization.

Addressing the gathering, Patel reaffirmed India's commitment to global pharmaceutical standardization and regulatory convergence. She highlighted India's role as the "Pharmacy of the World" and emphasized the importance of ensuring access to high-quality medicines globally. She stated that the IMWP serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization.

On this occasion, the Union Minister also released the IPC Newsletter 2024 and a special IPC video film, which showcase India's advancements in pharmacopoeial science and the Commission's efforts in ensuring high-quality pharmaceutical standards. The video film can be accessed at the following link: https://www.youtube.com/watch?v=MCdAZodvOSM .

Punya Salila Srivastava, Secretary, Ministry of Health and Family Welfare, underscored the significance of global partnerships in strengthening pharmaceutical quality standards. She reiterated India's efforts in aligning regulatory frameworks with international best practices and ensuring the availability of safe and effective medicines worldwide.

Dr. Rajeev Singh Raghuvanshi, Secretary-cum-Scientific Director, IPC, and Drugs Controller General (India), highlighted IPC's contributions in setting global benchmarks in pharmacopoeial science. He elaborated on IPC's initiatives, including the IP Online platform, which enhances accessibility and usability of Indian Pharmacopoeia standards. He emphasized the role of scientific advancements and regulatory cooperation in shaping global pharmaceutical standards.

Dr. Roderico H. Ofrin, WHO Representative to India, commended India's leadership in pharmacopoeial standard-setting and emphasized the importance of regulatory harmonization in ensuring patient safety and public health.

The 15th IMWP is set to facilitate discussions on key focus areas, including:

- Updates on recommendations from the 14th IMWP and review of progress on harmonization initiatives.

- Emerging issues in impurity assessment (Q3) and the implications of ICH Q6 guidelines on pharmacopoeial monograph specifications.

- Defining the IMWP Charter to establish a long-term governance structure for the forum.

- Enhancing collaboration among global pharmacopoeias and regulatory bodies, with updates from the Pharmacopoeial Discussion Group (PDG).

- Promotion of environmental sustainability in pharmacopoeial practices and pharmaceutical manufacturing standards.

- Finalization of reports for the 15th IMWP and preparatory discussions for the 16th IMWP.

The deliberations during the IMWP will reinforce the role of pharmacopoeias in ensuring the quality, safety, and efficacy of medicines. The outcomes of the meeting will guide future collaborations in standard-setting and regulatory harmonization.

The 15th IMWP, which commenced today, will conclude on 7th February 2025. The discussions held over these three days will set the stage for further strengthening global pharmacopoeial cooperation and enhancing pharmaceutical quality assurance.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.